October 16, 2023
BioNTech evaluates impact of Pfizer’s wirte-offs on financial results
BioNTech is evaluating the potential impact of Pfizer’s write-offs and other charges related to COMIRNATY on its financial results.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Pfizer
September 25, 2023
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
ABRYSVO recommended by CDC Advisory Committee for pregnant persons 32 through 36 weeks gestation to help protect infants from respiratory…
October 13, 2022
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of Pfizer BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.
April 26, 2022
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. have reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
April 13, 2022
FDA Doesn’t Give Myovant Sciences-Pfizer’s Pain Killer sNDA
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) have announced an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.
April 10, 2022
Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
April 7, 2022
Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
March 3, 2022
Pfizer’s RSV Vaccine Candidate Receives Breakthrough Therapy Designation for US
Pfizer has announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the…
February 2, 2022
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data…
January 19, 2022
Pfizer’s Paxlovid reduced risk of hospitalization or death by nearly 90% compared to placebo
Pfizer said Wednesday that the results from multiple studies showed the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron.